MedPath

Polyethylene glycol

Generic Name
Polyethylene glycol
Brand Names
Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
Drug Type
Small Molecule
CAS Number
25322-68-3
Unique Ingredient Identifier
3WJQ0SDW1A
Background

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.

Indication

Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.

Associated Conditions
Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
Associated Therapies
Bowel preparation therapy, Eye lubrication

Glenmark Therapeutics Enters OTC Constipation Market with Polyethylene Glycol 3350 Launch

• Glenmark Therapeutics has launched Polyethylene Glycol 3350 powder (17 grams/capful) as an over-the-counter constipation treatment in the US market, comparable to MiraLAX®. • The company enters a lucrative market segment that generated approximately $555.7 million in annual sales for the period ending February 2025, according to Nielsen® syndicated data. • This strategic product introduction addresses growing demand for alternative suppliers in the constipation treatment category, reinforcing Glenmark's commitment to expanding its OTC healthcare portfolio.

Network Meta-Analysis Reveals Comparable Efficacy Among Leading Chronic Constipation Treatments

• A comprehensive systematic review and network meta-analysis evaluated 21 randomized controlled trials involving 9,189 patients with chronic idiopathic constipation. • Multiple treatments including bisacodyl, sodium picosulfate, prucalopride, and velusetrag demonstrated superior efficacy compared to placebo in achieving complete spontaneous bowel movements. • While no single drug emerged as clearly superior for primary endpoints, bisacodyl showed potential advantages in improving weekly spontaneous bowel movement frequency.

ANI Pharmaceuticals Launches Prucalopride Tablets for Chronic Idiopathic Constipation with 180-Day Exclusivity

• ANI Pharmaceuticals has launched Prucalopride Tablets, a generic version of Motegrity, after receiving FDA approval and a Competitive Generic Therapy (CGT) designation. • Prucalopride, a selective 5-HT4 receptor agonist, enhances colon muscle movement to alleviate infrequent bowel movements in adults with chronic idiopathic constipation. • Clinical trials have demonstrated prucalopride's efficacy and safety in treating chronic constipation, showing a higher proportion of patients achieving at least 3 spontaneous bowel movements per week compared to placebo. • Real-world studies suggest prucalopride has higher treatment persistence and adherence compared to other prescription medications for chronic idiopathic constipation.

Perfusion Medical's PM-208 Receives $1.8 Million Grant from U.S. Air Force for Blood Loss Treatment

• Perfusion Medical secured a $1.8 million grant from the U.S. Air Force to advance PM-208, a novel treatment for massive blood loss injuries, bringing total military support to $7 million since 2023. • PM-208, developed by VCU's Dr. Martin Mangino, uses a specific formulation of polyethylene glycol to prevent ischemic reperfusion injuries by drawing water into capillaries. • Phase 1 clinical trials for PM-208 are expected to commence in early 2025, marking a significant step toward potential FDA approval and addressing a critical unmet medical need. • Preclinical studies in animal models have demonstrated that PM-208 significantly improves survival rates in cases of massive blood loss compared to current treatments like saline or blood transfusions.

Prucalopride Shows Favorable Safety Profile in Chronic Idiopathic Constipation Treatment

• Prucalopride, a selective 5-HT4 receptor agonist, demonstrates a manageable safety profile in treating chronic idiopathic constipation (CIC) based on clinical trial data. • Common adverse reactions reported in prucalopride-treated patients include headache, abdominal pain, nausea, and diarrhea, with most cases resolving within a few days. • Cardiovascular safety analysis from clinical trials and an observational cohort study did not indicate an increased risk of major adverse cardiovascular events (MACE) with prucalopride use. • Discontinuation rates due to adverse reactions were slightly higher in the prucalopride group compared to placebo, with nausea being the most common reason.

Comparative Evaluation of LaxaPlus Barij® and Polyethylene Glycol in Pediatric Functional Constipation

A randomized clinical trial compared the effectiveness of LaxaPlus Barij® and polyethylene glycol (4000) in treating functional constipation in children aged 2-15 years. The study found both treatments effective, with LaxaPlus Barij® showing a higher frequency of bowel movements and greater reduction in pain intensity and abdominal pain after 8 weeks of intervention.
© Copyright 2025. All Rights Reserved by MedPath